Helsinki Hematology Day 2020

---

Organized by the Clinical Research Institute HUCH and the Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology.
Date: Thursday February 13, 2020
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 8
Twitter: #HHD2020

PROGRAM

08:30	Coffee
09:00	Welcome and introduction	Ulla Wartiovaara-Kautto (@ullawk) Head of Hematology Department, Helsinki University Hospital Comprehensive Cancer Center
	Session I: Updates in malignant hematology (chair: U. Wartiovaara-Kautto)
09:10	Management of lower risk MDS	Antonio Almeida Professor, Head of Department at Hospital da Luz, Lisbon and Head of the Hemato-Oncology Diagnostic Laboratory, Portuguese Institute of Oncology, Lisbon, Portugal
09:50	AI/Machine learning in oncology/hematology	Moritz Gerstung (@MoritzGerstung) PhD in Computational Biology, The European Bioinformatics Institute (EMBL-EBI) Genome Campus, Cambridge, UK
10:40	Coffee, exhibitions
11:00	Molecular pathogenesis and therapy of myeloid malignancies	Ross L. Levine (@rosslevinemd) Professor, Laurence Joseph Dineen Chair in Leukemia Research; Director, MSK Center for Hematologic Malignancies,Memorial Sloan Kettering Cancer Center New York, USA
12:00	Lunch
	Session II: Updates in stem cell transplantation (chair: Riitta Niittyvuopio)
13:00	Welcome	Riitta Niittyvuopio Head of the transplantation unit, Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology
13:10	New from the Finnish Stem Cell Registry	Tiina Linjama M.D., Specialist, Finnish Stem Cell Registry, Helsink
13:40	Current options in CMV management after allogeneic HSCT	Per Ljungman Professor, Department of Hematology, Dept. of Medicine, and Director (act.), Dept. of Allogeneic Stem cell Transplantation, Karolinska Institutet, Stockholm, Sweden
14:20	Patient-specific MRD markers predicting relapse after allogeneic stem cell transplantation for patients with MDS; Results from the Nordic study NMDSG14B	Magnus Tobiasson M.D., PhD, Department of Medicine, Hematology, Karolinska Institutet, Stockholm, Sweden
15:00	Closing words	Riitta Niittyvuopio Head of the transplantation unit, Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology

 

Registration/ilmoittautuminen:

Eeva Lind-Ekholm (eeva.lind-ekholm@hus.fi, 09-471 74581) 01.02.2020 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Organized by the Clinical Research Institute HUCH and the Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology.
Date: Thursday February 18, 2021
Twitter #HHD2021 

 

Program

Morning

Time	Presenter	Title	Chair
	Kimmo Porkka	Opening words
09.00	John Gribben	First-line treatment of CLL	Kimmo Porkka
09.40	Robin Foà	Curing Ph+ALL	Kimmo Porkka
10.20		break
10.30	Luca Vago	Mechanisms of relapse after alloHSCT	Urpu Salmenniemi
11.10	Nicolas Kröger	Relapse prevention strategies after alloHSCT in AML and MDS	Urpu Salmenniemi
12.00		break
12.30	Fabio Ciceri	Keynote: COVID19 in hematological patients	Kimmo Porkka

 

Afternoon

Time	Presenter	Title	Chair
13.00	Lars Bullinger	Lessons from Harmony: case AML	Kimmo Porkka
13.40	Aarno Palotie	FinnGen – facilitating genomic research and patient care	Ulla Wartiovaara-Kautto
14.20	Merja Heinäniemi	Utilizing big data in hematology research	Ulla Wartiovaara-Kautto
	Ulla Wartiovaara-Kautto	Closing words

 

Link to registration. 

teksti

Helsinki Hematology Day 2018

---

Organized by Helsinki University Hospital Comprehensive Cancer Center/Dept. of Hematology, Clinical Research Institute HUCH and The Finnish Leukemia Group.
Date: Thursday February 15, 2018
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 8

PROGRAM

08:30	Coffee
09:00	Welcome and introduction	Kimmo Porkka Professor, Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology
	Session I: Updates in hematology (chair: K. Porkka)
09:00	Novel therapy options for MDS	Kirsten Grønbæk Professor, Department of Hematology, Rigshospitalet, Copenhagen
09:40	Personalized treatment of acute leukemia	Jude Fitzgibbon Professor of Personalised Cancer Medicine, Barts Cancer Institute, London
10:20	Coffee, exhibitions
10:40	Update on coagulation medicine	Riitta Lassila Professor, Helsinki University Hospital Comprehensive Cancer Center, Coagulation Disorders Unit
11:20	Crossing the line between cancer and autoimmunity	Satu Mustjoki Professor of translational hematology, Hematology Research Unit Helsinki, University of Helsinki
12:00	Lunch
	Sessio II: kantasolujensiirrot - back to basics (pj Maija Itälä-Remes)
13:00	CMV-infektion diagnostiikka ja hoito	Maija Itälä-Remes Ylilääkäri, HYKS Syöpäkeskus, hematologian klinikka
13:40	Vaikean aplastisen anemian hoito	Mikko Keränen Erikoistuva lääkäri, HYKS Syöpäkeskus, hematologian klinikka
14:10	Allogeenisen kantasolujensiirron indikaatiot MDS-taudissa	Riitta Niittyvuopio Erikoislääkäri, HYKS Syöpäkeskus, hematologian klinikka, kantasolujensiirtoyksikkö
14:45	Päätössanat	Maija Itälä-Remes Ylilääkäri, HYKS Syöpäkeskus, hematologian klinikka, kantasolujensiirtoyksikkö

 

Registration/ilmoittautuminen:

Eeva Lind-Ekholm (eeva.lind-ekholm@hus.fi, 09-471 74581) 02.02.2018 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Meilahti Hematology Day 2011 Organized by HUCH/hematology and Finnish Leukemia Group Friday February 18, 2011, Haartman Institute, lecture hall 1, Haartmaninkatu 3

Program

08.30	Coffee
08.50-09.00	Welcome and introduction	Kimmo Porkka
	Session I: State of the art (chair: K. Porkka)
09.00-09.40	Personalized medicine for leukemia	Olli Kallioniemi
09.40-10.20	Chemosensitization in acute myeloid leukemia	Gert Ossenkoppele
10.20-10.40	Coffee
10.40-11.20	Strategies for curative drug therapy of CML	Giuseppe Saglio
11.20-12.00	Insights from population-based registry studies	Magnus Björkholm
12.00-12.15	Sponsors	Celgene, Genzyme, Novartis
12.15-13.00	Lunch
	Session II: Finnish Leukemia Group therapy guidelines (chair: Marjaana Säily)
13.00-13.20	SHR	Perttu Koskenvesa
13.20-13.40	AML	Pirjo Koistinen
13.40-14.00	Multippeli myelooma	Raija Silvennoinen
14.00-14.20	KLL	Maija Itälä
14.20-14.40	KML	Satu Mustjoki
14.40-15.00	Kahvi
15.00-15.20	MDS	Timo Siitonen
15.20-15.40	Kansalliset potilasohjeet	Sari Haavisto
15.40-16.00	FHRB	Kimmo Porkka
16.00	Loppusanat	Kimmo Porkka

Tervetuloa !

Ilmoittautuminen:

Ruokajärjestelyjen vuoksi ilmoittautuminen sihteeri Eeva Mäkiselle, e-mail: eeva.makinen@hus.fi, puh. 09-471 74581 viimeistään 4.2.2010. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Helsinki Hematology Day 2013

Organized by HUCH/hematology, Clinical Research Institute HUCH and The Finnish Leukemia Group.
Date: Thursday February 14, 2013
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 4

 

Ohjelma/Program

08.30	Coffee
08.50-09.00	Welcome and introduction	Kimmo Porkka Helsinki University Central Hospital
	Session I: State of the art (chairs: K. Porkka, R. Lassila)
09.00-09.40	Coagulation in 2013	Robert Flaumenhaft BIDMC/Harvard Medical School, Boston
09.40-10.20	Genetic markers in AML: will the promise of improving treatment outcomes be realized?	Charles Schiffer Wayne State University School of Medicine, Detroit
10.20-10.40	Coffee, exhibitions
10.40-11.20	Curative therapy for mantle-cell lymphoma	Christian Geisler Rigshospitalet, Copenhagen
11.20-12.00	Update on systemic mastocytosis	Peter Valent Medical University of Vienna
12.00-13.00	Lunch, exhibitions
	Session II: Finnish Leukemia Group therapy guidelines and studies (chair: Marjatta Sinisalo)
13.00-13.30	Neutropeeninen enterokoliitti	Maria Rämet, Tays
13.30-14.00	Leukemiapotilaiden hemostaasiongelmat	Ulla Wartiovaara-Kautto, HUS
14.00-14.30	Myeloomaryhmän tutkimus (FMG-MM02) ja  päivitystä ohjeistoon	Raija Silvennoinen, KYS
14.30-15.00	Pneumokokkirokotukset hematologisilla potilailla	Vesa Lindström, HUS
15.30-16.00	FHRB-tilannekatsaus	Perttu Koskenvesa, HUS
16.00	Tilaisuus päättyy

Registration/ilmoittautuminen:
Eeva Mäkinen (eeva.makinen@hus.fi, 09-471 74581) 04.02.2013 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Helsinki Hematology Day 2014

---

Organized by HUCH/hematology, Clinical Research Institute HUCH and The Finnish Leukemia Group.
Date: Thursday February 13, 2014
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 4

PROGRAM

08.30	Coffee	Edit
08.50	Welcome and introduction	Prof. Kimmo Porkka Helsinki University Central Hospital Cancer Center
	Session I: From molecular pathogenesis to targeted therapy (chair: K. Porkka)
09.00	LGL-leukemia	Prof. Thomas P. Loughran, Jr. University of Virginia Cancer Center, Charlottesville
09.40	MDS	Prof. Eva Hellström Lindberg Karolinska Institute, Stockholm
10.20	Coffee, exhibitions
10.40	ALL	Prof. Kjeld Schmiegelow University Hospital Rigshospitalet, Copenhagen
11.20	Immunotargeting: engineered cells and checkpoint antibodies	Dr. Marcela V. Maus University of Pennsylvania, Philadelphia
12.00	Lunch
	Session II: SLR:n hoito-ohjeita ja tutkimuksia/ Finnish Leukemia Group therapy guidelines and studies (pj/chair: Marja Sankelo)
13.00	ALL-hoito-ohjelma	Dos. Erkki Elonen, HUS
13.30	Ajankohtaista myeloomatutkimuksista	Erik.lääk. Raija Silvennoinen, KYS
14.00	Kahvitauko
14.20	Ajankohtaista MDS:sta kliinikolle	Dos. Freja Ebeling, HUS
14.40	FHRB tilannekatsaus	Erik. lääk. Mika Kontro, HUS
15.10	SLR:n alkuvaiheista	Prof. Ilmari Palva
15.45	Päätössanat

 

Registration/ilmoittautuminen:

Eeva Lind (eeva.lind@hus.fi, 09-471 74581) 05.02.2014 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Helsinki Hematology Day 2015

---

Organized by HUCH/hematology, Clinical Research Institute HUCH and The Finnish Leukemia Group.
Date: Thursday February 12, 2015
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 4

PROGRAM (click title for presentation slides, when available)

08.30	Coffee
08.50	Welcome and introduction	Kimmo Porkka Professor, head of depaprtment, University of Helsinki and Helsinki University Hospital Cancer Center
	Session I: Genomics and clinics (chair: K. Porkka)
09.00	Genetics of MDS, MPNs and the overlap syndromes	Nicholas C.P. Cross Professor, director, University of Southampton and Wessex Regional Genetics Laboratory
09.40	AML in elderly	Bjorn Tore Gjertsen Professor, University of Bergen
10.20	Coffee, exhibitions
10.40	CLL: from molecular pathogenesis to targeted therapy	Michael Hallek Professor, University of Cologne
11.20	Individualized Systems Medicine (ISM) in hematological cancers	Caroline Heckman Principal Investigator, Finnish Institute for Molecular Medicine, University of Helsinki
12.00	Lunch
	Sessio II: SHY:n Veritautien hoito- ja tutkimusryhmä (pj Taru Kuittinen)
13.00	Lääkeherkkyystutkimukset myeloomassa	Raija Silvennoinen KYS
13.30	Ajankohtaista veritautien hoidosta ja tutkimuksista	Tautikohtaiset alaryhmät
14.30	Päätössanat	Kimmo Porkka

 

Registration/ilmoittautuminen:

Eeva Lind (eeva.lind@hus.fi, 09-471 74581) 03.02.2015 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Helsinki Hematology Day 2016

---

Organized by Helsinki University Hospital Comprehensive Cancer Center/Dept. of Hematology, Clinical Research Institute HUCH and The Finnish Leukemia Group.
Date: Thursday February 18, 2016
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 4

PROGRAM

08:30	Coffee
08:50	Welcome and introduction	Kimmo Porkka Professor, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center
	Session I: State of the art (chair: K. Porkka)
09:00	Path to cure: TKI discontinuation in CML	Johan Richter Professor, Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund
09:40	CLL: something old, something new	Susan O'Brien Professor, Division of Hematology/Oncology School of Medicine, University of Irvine, USA
10:20	Coffee, exhibitions
10:40	Bispecific antibodies	Max S. Topp Professor, University Hospital of Würzburg
11:20	Induction of hemophilia inhibitor tolerance	Elina Armstrong Coagulation Disorders Unit, Helsinki University Hospital Comprehensive Cancer Center
12.00	Lunch
	Sessio II: SHY:n Veritautien hoito- ja tutkimusryhmä (pj Raija Silvennoinen)
13:00	Next-generation sequencing: clinical applications	Richard Rosenquist Brandell Professor, SciLifeLab and Rudbeck Laboratory, Uppsala University
13:30	Hematologiset potilasverkostot	Minni Peltonen, verkostokoordinaattori Suomen Syöpäpotilaat ry
13.45	Ajankohtaista veritautien hoidosta ja tutkimuksista	Tautikohtaiset alaryhmät
14:45	Päätössanat	Kimmo Porkka

 

Registration/ilmoittautuminen:

Eeva Lind-Ekholm (eeva.lind-ekholm@hus.fi, 09-471 74581) 03.02.2016 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Helsinki Hematology Day 2017

---

Organized by Helsinki University Hospital Comprehensive Cancer Center/Dept. of Hematology, Clinical Research Institute HUCH and The Finnish Leukemia Group.
Date: Thursday February 16, 2017
Location: Biomedicum Helsinki, lecture hall 2, Haartmaninkatu 8

PROGRAM

08:30	Coffee
08:50	Welcome and introduction	Kimmo Porkka Professor, Helsinki University Hospital Comprehensive Cancer Center
	Session I: State of the art (chair: K. Porkka)
09:00	Novel therapy options for AML	Richard M. Stone Professor, Dana-Farber Cancer Institute, Boston, MA
09:40	Towards curative drug therapy for Ph+ALL	Farhad Ravandi Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
10:20	Coffee, exhibitions
10:40	Role of novel antibodies in multiple myeloma	Pieter Sonneveld Professor, Erasmus University, Rotterdam
11:20	Update on CAR T-cell therapy	Justin Eyquem Research fellow, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
12:00	Lunch
	Sessio II: SHY:n Veritautien hoito- ja tutkimusryhmä (pj Raija Silvennoinen)
13:00	Suomen myeloomaryhmä (FMG) Myelooman uudet lääkkeet relapsin hoidossa - Pekka Anttila  FMG - Myeloomatutkimukset: IRd ja KEd - Raija Silvennoinen FMG - MM02 virtaussytometrialöydöksiä  - Sini Luoma
13:45	Suomen Leukemiaryhmä: AML-update	Maija Itälä-Remes
14:00	Hemofiliaryhmä	Anne Mäkipernaa
14:15	Nordic CML Study Group: update	Perttu Koskenvesa
14:30	PNH-ryhmä	Elina Armstrong
14:45	Päätössanat	Kimmo Porkka

 

Registration/ilmoittautuminen:

Eeva Lind-Ekholm (eeva.lind-ekholm@hus.fi, 09-471 74581) 03.02.2017 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Helsinki Hematology Day 2019

---

Organized by the Clinical Research Institute HUCH and the Helsinki University Hospital Comprehensive Cancer Center/Dept. of Hematology.
Date: Thursday February 14, 2019
Location: Biomedicum Helsinki, lecture hall 1, Haartmaninkatu 8

PROGRAM

08:30	Coffee
09:00	Welcome and introduction	Kimmo Porkka Professor, Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology
	Session I: Updates in hematology (chair: K. Porkka)
09:00	Genome-driven therapy of ALL	Charles Mullighan Professor, Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
09:40	Clinical implications of clonal hematopoiesis	Lambert Busque Professor of Medicine, Université de Montréal, and Chief of Molecular Diagnostic and Coordinator of the Cancer Program, Hôpital Maisonneuve-Rosemont, Montréal, Québec
10:20	Coffee, exhibitions
10:40	Targeted therapy of AML	Jorge Cortes Professor, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
11:20	Clinical trials of hematology: are we testing trivialities?	Vinay Prasad Assistant Professor of Medicine, Division of Hematology Oncology in the Knight Cancer Institute, OHSU, Portland, OR
12:00	Lunch
	Session II: Updates in stem cell transplantation
13:00	Welcome	Riitta Niittyvuopio Head of the transplantation unit, Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology
13:00	DLI and pharmacologic interventions post allo-HSCT	Jürgen Kuball Professor, Department of Hematology, Utrecht Cancer Center
13:50	Terveisiä Veripalvelusta	Tiina Linjama Erikoislääkäri, SPR Veripalvelu, Helsinki
14:20	Allogeenisen kantasolusiirtopotilaan gynekologinen hoito ja seuranta	Elina Holopainen LT, Naistentautien ja synnytysten erikoislääkäri, HUS

 

Registration/ilmoittautuminen:

Eeva Lind-Ekholm (eeva.lind-ekholm@hus.fi, 09-471 74581) 01.02.2019 mennessä. Mainitsethan samalla mahdollisesta erityisruokavaliosta.

Welcome! Tervetuloa!
 

Esitykset liitteenä. 

Ilkka Kunnamon luento: Yksilöllistetyn hoidon vaikuttavuus ja kustannusvaikuttavuus 

http://bit.ly/2fTbQdU

Esitykset alla liitetiedostona (vaatii kirjautumisen). 

TURKU SYMPOSIUM XIII ON STEM CELL TRANSPLANTATIONS 11.11.2011

TURKU UNIVERSITY HOSPITAL; AUDITORIUM AT T-HOSPITAL

Tentative Program

12.30   Opening                                                         

Session 1:  Molecular biology

12.45   Molecular mechanisms in cancer                              J Westermarck, Turku

                                                           

Session 2: Donor choice

13.30   Current issues of the Finnish Donor Registry            T Linjama,  Helsinki

14.00   Choice of unrelated donor                                        J Finke, Freiburg

14.45   Coffee break

Session 3:  Acute leukaemias

15.30   Finnish Leukemia Group Trials                                  E Elonen, Helsinki

16.10   Translational research in AML                                   K Porkka, Helsinki        

16.50   Allotransplantation in refractory AML ; the

            Turku experience                                                     Maija Itälä-Remes, Turku

17.15   Transplantation of chemorefractory acute leukaemia J Finke, Freiburg      

18.00   End of Symposium

18.30   Symposium Dinner

XIV TURUN KANTASOLUSIIRTOSYMPOSIUMI 6.11.2012

(Turun XXIX Lääketiedepäivien Tieteellinen Symposiumi)

Turun Kantasolusiirto-ohjelma/ TYKS / Sisätautien klinikka

Paikka: Mauno Koivisto -keskus, BioCity, Tykistökatu 6, Turku

 

Ohjelma

10.00   Opening                                                           K Remes, Turku       

Sessio 1:  Perustietämystä

10.15   Immunologinen toipuminen allogeenisen kantasolusiirron jälkeen    K Vettenranta, Tampere

10.45   Uudet molekyyligeneettiset menetelmät hematologiassa                    V Kairisto, Turku

Session 2:   Infections in hematopoietic stem cell allotransplantations                     

11.15   Need of fungal prophylaxis in AML and allotransplantation               P Donnelly, Nijmegen

11.45   Incidence of fungal infections in allotransplants; Turku experience   U Salmenniemi, Turku

12.05   Coffee break

13.10   Treatment of deep fungal infections                            J Oksi, Turku

13.40   CMV: prophylactic or preemptive therapy ?                                                 H Einsele, Wurzburg

Session 3:  State of the art lecture

14.15   Use of donor lymphocyte infusions after allogeneic HSCT                JH Falkenburg, Leiden

15.00   Coffee break

Sessio 4:  Allogeenisen kantasolusiirron pitkäaikaisseuraamukset

15.30   Allogeenisen kantasolusiirron jälkiseuranta                             M Itälä-Remes, Turku

15.55   Siirron jälkeiset sekundaarisyövät: Turun kokemukset                       M Kauppila, Turku

16.15   Symposiumin päätös

18.00  Symposiumi-illallinen, Ravintola Hus Lindman

Tilaisuus on maksuton.

Symposiumia on anottu erikoislääkärikoulutuksen teoreettiseksi kurssimuotoiseksi koulutukseksi seuraaville erikoisaloille: kliininen hematologia, kliininen kemia, lastentaudit, sisätaudit ja syöpätaudit.

Ilmoittautuminen osallistumisesta symposiumiin ja illalliselle (sis. erityisruokavaliotoiveet)

31.10.2012 mennessä joko www.turunlaaketiedepaivat.info tai helena.jarvio@tyks.fi

XV TURUN KANTASOLUJENSIIRTOSYMPOSIUM 25.10.2013

Järj.: TYKS/ Medisiininen toimialue/ Turun kantasolujensiirtoyksikkö

Paikka: TYKS, T-sairaala, Hämeenkatu 11, Johan Haartman -luentosali

OHJELMA

12.00   Kahvi ja virvokkeita; näyttely

13.00   Opening                                                          M Itälä-Remes, Turku

13.10             Survey on allotransplants in Turku 2000-2010                         K Remes, Turku 

 

Session 1:   CHRONIC LYMPHOCYTIC LEUKEMIA

13.30   SCT in CLL: state of the art                                        P Dreger, Heidelberg

14.10               Update of SCT for CLL in Turku                               M Putkonen, Turku

 

Session 2:   MYELOPROLIFERATIVE NEOPLASIAS

14.30   Update of transplants for myelofibrosis in Turku                 M Kauppila, Turku

14.50   Allogeneic transplantations in MPNs – to whome and when? B Andreasson, Göteborg

 

15.35   Kahvitauko; näyttely

 

Session 3: ACUTE MYELOID LEUKEMIA

16.15             Allotransplantations for refractory AML                                T Pfeiffer, Augsburg

16.55             Update of allotransplants for refractory AML in Turku            M Itälä-Remes, Turku

 

17.20   Close of Symposium

 

18.00            Symposium Dinner at Restaurant Svenska Klubben

 

Ilmoittautuminen 18.10.2013 mennessä helena.jarvio@tyks.fi, samalla ilmoittautuminen myös illalliselle mahdollisin ruokavaliotoivein.

Tiedustelut kari.remes@tyks.fi tai 02-313 0016.

 

 

 

Liittenä vuoden 2019 ohjelma ja luennot. Nähtävillä kuukauden jonka jälkeen vaatii kirjautumisen (SHY-jäsenyys). 

Ohjelma ja luennot liitteenä (vaatii kirjautumisen)

 

ESH-EHA Scientific Workshop AML "Molecular" 

October 14-16, 2011 - Mandelieu La Napoule, France. Chairs : B. Löwenberg, Hartmut Döhner

Short report by Kimmo Porkka

The meeting was exceptionally good. Central themes were epigenetics (pathogenesis and therapeutics), stem cell niches, FLT3, NPM1. Some brief comments on few of the presentations (the biological part). 

Signaling pathways in leukemic stem cells. S. Armstrong (Boston)

• Examples of a cancer driven by mutations involving an epigenetic regulator are leukemias bearing translocations involving the Mixed Lineage Leukemia (MLL) gene at 11q23. MLL-rearranged leukemias account 10% leukemias (ALL, AML). >70 fusion partners described. Associated with a poor prognosis both in children and in adults
• Speaker studied MLL-fusion targets in an MLL-AF9 leukemia model, and conducted epigenetic profiling for H3K79me2, H3K4me3, H3K27me3, and H3K36me3 in hematopoietic progenitor and leukemia stem cells (LSCs).
• Loss of Dot1l selectively decreased expression of MLL fusion-driven transcriptional programs. The aberrant H3K79 methylation pattern and the specific requirement of H3K79 methylation for the maintenance of the MLL translocation-associated oncogenic program demonstrated that MLL-rearranged leukemias are driven by an aberrant epigenetic program. This has profound therapeutic implications because Dot1l is one of few enzymes linked to MLL-fusion proteins and, as such, may represent an important therapeutic target.
• Preclinical data on a small molecule Dot1 inhibitor presented, promising
• Related paper: Cancer Cell. 2011 Jul 12;20(1):66-78.
• A nice recent review on MLL: Br J Haematol. 2011 Jan;152(2):141-54

CEBPA mutants, stem cells and leukemogenesis. C. Nerlov (Edinburgh) 

• CEBPA-mutations in 9% de novo AML. A transcription facotor and an epigenetic modulator.
• Combined N- and C-terminal CEBPA-mutations collaborate in leukemogenesis and induce erythroid reprogramming and expansion of pre-leukemic stem cells with sufficient myeloid lineage commitment to generate leukemia initiating cells. In concord, often associated with FLT3-ITD mutations
• Related paper: Cancer Cell. 2009 Nov 6;16(5):390-400.

Molecular basis for APL cure by retinoic acid and arsenic. H. de Thé (Paris)

• Retinoic acid (RA) rapidly induces massive differentiation of blasts into neutrophils in t(15;17) with PML-RARA-fusion in acute promyelocytic leukemia (APL), but rarely if ever cures patients as monotherapy. In combination with an anthracycline/cytarabine cures >80% of APLs.
• Arsenic trioxide had been used in treating malignancies from the 18th to mid-20th century and has been shown to induce complete remissions in APL.
• RA+arsenic curative in mice and in patients: combination synergises for PML-RARA oncogene degradation and rapidly clears leukemia-initiating cells. Oncogene degradation could be a generally applicable strategy to eradicate cancer stem cells in many types of tumors.
• Applicable to other leukemias: addition of RA to chemotherapy improves responses in NPM1-positive AMLs (Haematologica. 2009 Jan;94(1):54-60), combination with arsenic even more effective?
• Related paper: Science. 2010 Apr 9;328(5975):240-3
• Recent reviews from the group: Nat Rev Cancer. 2010 Nov;10(11):775-83, Blood. 2011 Jun 2;117(22):5795-802.

Stress-induced activation of HSC's. A. Trumpp (Heidelberg)

• Virus/tumor-induced IFNa and LPS from gram- bacteria induce cycling of HSC's ina a SCA-1-dependent manner
• Recent paper showing activation of dormant HSC's by IFNa: Nature. 2009 Apr 16;458(7240):904-8.
• Recent review: Nat Rev Immunol. 2010 Mar;10(3):201-9

The vascular niche. D. Sipkins (Chicago)

• A very nice talk on on the BM microenvironment. At least two major HSPC niches exist within the bone marrow — the perivascular niche and the endosteal (or bone) niche.
• In vivo confocal and multiphoton microscopy studies in mice show that leukemic cells hijack the normal HSC niche signalling pathways to enter the BM. Dynamic interplay between leukemia and the BM niche critically regulates leukemic growth and is a therapeutic target.
• Related paper: Science. 2008 Dec 19;322(5909):1861-5
• Related commentary: Cell Stem Cell. 2010 Dec 3;7(6):645-6

Fanconi anemia pathway and AML. K. J. Patel (Cambridge)

• Fanconi anaemia (FA) is a chromosome-breakage disease that causes developmental defects, sterility, bone-marrow failure and a highly elevated risk of cancer, AML in particular. Mutations in 15 genes are known to be associated with this disorder (incl. BRAC2). Cells carrying FA-associated mutations are exceptionally sensitive to the crosslinking agent acetaldehyde, a highly reactive substance and can damage DNA, and can cause crosslinking.
• Patel's work provides strong evidence that metabolically produced acetaldehyde (e.g. from ethanol)  is a potential driver of endogenous DNA damage, which is normally counteracted by acetaldehyde detoxification, in conjunction with DNA repair through the FA pathway.
• Significant implications: ethanol consumption is genotoxic through the accumulation of acetaldehyde, potentially causing fetal damage (for instance, fetal alcohol syndrome), bone-marrow dysfunction and increased prevalence of cancers. Could also be therapeutically utilized in leukemia (preclinical experiments ongoing): ethanol + antabus!
• Related papers from the group: Nature. 2011 Jul 6;475(7354):53-8, Nat Genet. 2011 Feb;43(2):147-5, Science. 2010 Jul 9;329(5988):219-23

Interrogating the architecture of cancer genomes by deep sequencing. P. Campbell (Cambridge)

• Referenced their very nice paper on exome sequencing of 9 MDS RARS patients: N Engl J Med. 2011 Oct 13;365(15):1384-1395

Disease gene identification in preleukemic disorders. O. Bernard (Paris)

• Reviewed his recent paper on TET2-mutations in CMML and lymphomas. Cancer Cell. 2011 Jul 12;20(1):25-38

Small molecule phenotypic screening to identify inducers of megakaryocyte polyploidization as targeted therapy for AML. J.D. Crispino (Chicago)

• Performed a high-throughput screen on >1000 small molecule compounds: AML cells incubated with compunds 72h, fixed, analyzed for moprhology and DNA content (e.g. proliferation, apoptosis) using Cell Profiler software from Broad institute. Identified >200 small molecules, focused on diMF compound, found its target to be ROCK1 kinase. A very promising differentiation therapy for AMKL.

Identification of candidate AML drug targets using. S. Fröhling (Ulm)

• Homeobox gene CDX2 is aberrantly expressed in 90% of acute myeloid leukemia and promotes leukemogenesis
• PPAR gamma agonists (anti-diabetic drugs in development) a novel potential therapeutic agent for CDX2-driven AML 

Methylome mapping of hematopoietic stem cells: epigenetic basis of hematopoietic differentiation and de-differentiation. A. Feinberg (Baltimore)

• A really great and visionary talk, novel concept on the central role of epigenetics in cancer initiation.
• In a comprehensive analysis of common cancer types, a high degree of stochastic variation in methylation within each tumor type, but involving the same loci across tumor types. A hypothesis: stochastic epigenetic variation is a driving force for development, adaptation and disease.     
• For more details, have a look at the related papers: Nat Genet. 2011 Jun 26;43(8):768-75, Nat Struct Mol Biol. 2011 Jul 3;18(8):867-74, Nature. 2010 Sep 16;467(7313):338-42

 

EVI1-positive AML R. Delwel (Rotterdam)

Epigenetic profiling of AML A. Melnick (New York)
MicroRNA profiling G. Marcucci (Columbus)
Identification and characterization of miRNA controlled pathways in AML S. Erkeland (Rotterdam)
Molecular diagnostic stratification C. Bloomfield (Columbus)
CEBPA mutations in AML P. Valk (Rotterdam)
Molecular diagnostic stratification A. Burnett (Cardiff)
NPM1 mutation as a molecular marker to monitor MRD in AML K. Döhner (Ulm)
Flow cytometric MRD assessment : clinical consequences G. Ossenkoppele (Amsterdam)
Combined epigenetic therapy K. Bhalla (Kansas)
Targeting of abnormal repair of double strand breaks F. Rassool (Baltimore)
AML stem cell priming J. Dipersio (Washington)
Identification, characterisation and therapeutic targeting of myelodysplastic syndrome stem cells S. E. W. Jacobsen (Oxford)
Update on FLT3 inhibition T. Fischer (Magdeburg)
Targeting mTOR/protein translation D. Bouscary (Paris)
Pathogenesis and Therapy of IDH‐mutant leukemias R. Levine (New York)
Novel drugs in clinical trial for AML. F. Giles (Galway)